Herramientas para un ajuste de dosis de tacrolimus más personalizado en el seguimiento de los pacientes con transplante renal. Fenotipo metabolizador según polimorfismos genéticos del CYP3A vs. el cociente concentración-dosis

Vidal Alabró, Anna; Colom, Helena; Fontova, Pere; Cerezo, Gema; Melilli, Edoardo; Montero, Núria; Coloma, Ana; Manonellas, Anna; Favà, Alexandre; Cruzado, Josep M.
Nefrología (Madrid) ; 44(2): 204-216, Mar-Abr. 2024. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-231570

Documentos relacionados

  1. Tools for a personalized tacrolimus dose adjustment in the follow-up of renal transplant recipients. Metabolizing phenotype according to CYP3A genetic polymorphisms versus concentration-dose ratio.
  2. Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis.
  3. The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.
  4. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus.
  5. Effect of CYP3A4*22, CYP3A5*3 and POR*28 genetic polymorphisms on calcineurin inhibitors dose requirements in early phase renal transplant patients.
  6. Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies.
  7. Physiologically based pharmacokinetic model combined with reverse dose method to study the nephrotoxic tolerance dose of tacrolimus.
  8. Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers.
  9. Low-dimensional neural ODEs and their application in pharmacokinetics.
  10. [Advantages of population pharmacokinetics and its application in the field of traditional Chinese medicine].